Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology

SHANGHAI, Sept. 10, 2023 /PRNewswire/ — Dizal today announced the publication of the Phase I clinical data of golidocitinib for the treatment of relapsed or refractory (r/r) peripheral T cell lymphomas (PTCL) (JACKPOT8 PARTA) in Annals of Oncology (2022-2023 Impact Factor: 51.8). PTCL is…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.